MK5 is degraded in response to doxorubicin and negatively regulates doxorubicin-induced apoptosis in hepatocellular carcinoma cells

Biochemical and Biophysical Research Communications

Volumn 427, Issue 3, 2012, Pages 581-586

  Zhou, Jun ^a   Wan, Bo ^a   Liu, Xiao Min ^b   Li, Ruwei ^a   Wang, Yingli ^a   Yu, Long ^a  

^a FUDAN UNIVERSITY   (China)

^b Gyeongsang National University   (South Korea)

Author keywords

Apoptosis; Degradation; Doxorubicin; Hepatocellular carcinoma; MK5

Indexed keywords

CASPASE 3; DOXORUBICIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; P38 REGULATED ACTIVATED PROTEIN KINASE; PROTEASOME; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME INDUCTION; GENE OVEREXPRESSION; GENE SILENCING; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-SERINE-THREONINE KINASES; PROTEOLYSIS; UP-REGULATION;

EID: 84867872344     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.09.101     Document Type: Article

References (30)

1. Chen M., Therneau T., Orsini L.S., Qiao Y.-L. Design and rationale of the HCC BRIDGE study in China: a longitudinal, multicenter cohort trial in hepatocellular carcinoma. BMC Gastroenterol. 2011, 11:53.
2. Miki D., Ochi H., Hayes C.N., Aikata H., Chayama K. Hepatocellular carcinoma towards personalized medicine. Cancer Sci. 2012, 103:846-850.
3. Llovet J.M. Updated treatment approach to hepatocellular carcinoma. J. Gastroenterol. 2005, 40:225-235.
4. Lee T.K., Lau T.C., Ng I.O. Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Cancer Chemoth. Pharm. 2002, 49:78-86.
5. Marquardt J.U., Galle P.R., Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J. Hepatol. 2012, 56:267-275.
6. Yeo W., Mok T.S., Zee B., Leung T.W., Lai P.B., Lau W.Y., Koh J., Mo F.K., Yu S.C., Chan A.T., Hui P., Ma B., Lam K.C., Ho W.M., Wong H.T., Tang A., Johnson P.J. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl. Cancer Inst. 2005, 97:1532-1538.
7. New L., Jiang Y., Zhao M., Liu K., Zhu W., Flood L.J., Kato Y., Parry G.C.N., Han J. PRAK, a novel protein kinase regulated by the p38 MAP kinase. EMBO J. 1998, 17:3372-3384.
8. Ni H., Wang X.S., Diener K., Yao Z. MAPKAPK5 a Novel mitogen-activated protein kinase. Biochem. Biophys. Res. Commun. 1998, 243:492-496.
9. Sun P., Yoshizuka N., New L., Moser B.A., Li Y., Liao R., Xie C., Chen J., Deng Q., Yamout M., Dong M.Q., Frangou C.G., Yates J.R., Wright P.E., Han J. PRAK is essential for ras-induced senescence and tumor suppression. Cell 2007, 128:295-308.
10. Kress T.R., Cannell I.G., Brenkman A.B., Samans B., Gaestel M., Roepman P., Burgering B.M., Bushell M., Rosenwald A., Eilers M. The MK5/PRAK kinase and Myc form a negative feedback loop that is disrupted during colorectal tumorigenesis. Mol. Cell. 2011, 41:445-457.
11. Yoshizuka N., Chen R.M., Xu Z., Liao R., Hong L., Hu W.Y., Yu G., Han J., Chen L., Sun P. A novel function of p38-regulated/activated kinase in endothelial cell migration and tumor angiogenesis. Mol. Cell. Biol. 2012, 32:606-618.
12. New L., Jiang Y., Han J. Regulation of PRAK subcellular location by p38 MAP kinases. Mol. Biol. Cell. 2003, 14:2603-2616.
13. Li Q., Zhang N., Zhang D., Wang Y., Lin T., Zhou H., Ye Z., Zhang F., Lin S.C., Han J. Determinants that control the distinct subcellular localization of p38alpha-PRAK and p38beta-PRAK complexes. J. Biol. Chem. 2008, 283:11014-11023.
14. Cuenda A., Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. BBA-Mol. Cell. Res. 2007, 1773:1358-1375.
15. Cuadrado A., Nebreda A.R. Mechanisms and functions of p38 MAPK signalling. Biochem. J. 2010, 429:403-417.
16. Park J., Yuk Y., Rhim H., Yi S., Yoo Y.S. Role of p38 MAPK in the regulation of apoptosis signaling induced by TNF-α in differentiated PC12 cells. J. Biochem. Mol. Biol. 2002, 35:267-272.
17. Rodriguez-Garcia M.E., Quiroga A.G., Castro J., Ortiz A., Aller P., Mata F. Inhibition of p38-MAPK potentiates cisplatin-induced apoptosis via GSH depletion and increases intracellular drug accumulation in growth-arrested kidney tubular epithelial cells. Toxicol. Sci. 2009, 111:413-423.
18. Liu G., Jiang S., Wang C., Jiang W., Yu L., et al. Zinc finger transcription factor 191, directly binding to β-Catenin promoter promotes cell proliferation of hepatocellular carcinoma. Hepatology 2012, 55:1830-1839.
19. Xiao Q., Qu K., Wang C., Kong Y., Liu C., Jiang D., Saiyin H., Jia F., Ni C., Chen T., Zhang Y., Zhang P., Qin W., Sun Q., Wang H., Yi Q., Liu J., Huang H., Yu L. HDGF-related protein-3 is required for anchorage-independent survival and chemoresistance in hepatocellular carcinomas. Gut 2012.
20. Poizat C., Puri P.L., Bai Y., Kedes L. Phosphorylation-dependent degradation of p300 by doxorubicin-activated p38 mitogen-activated protein kinase in cardiac Cells. Mol. Cell. Biol. 2005, 25:2673-2687.
21. Frenzel A., Zirath H., Vita M., Albihn A., Henriksson M.A. Identification of cytotoxic drugs that selectively target tumor cells with MYC overexpression. PloS One 2011, 6:27988.
22. Chen J., Shen B.Y., Deng X.X., Zhan Q., Peng C.H. SKP1-CULLIN1-F-box (SCF)-mediated DRG2 degradation facilitated chemotherapeutic drugs induced apoptosis in hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 2012, 420:651-655.
23. Ranek M.J., Wang X. Activation of the ubiquitin proteasome system in doxorubicin cardiomyopathy. Curr. Hypertens. Rep. 2009, 11:389-395.
24. Persaud A., Alberts P., Amsen E.M., Xiong X., Wasmuth J., Saadon Z., Fladd C., Parkinson J., Rotin D. Comparison of substrate specificity of the ubiquitin ligases Nedd4 and Nedd4-2 using proteome arrays. Mol. Syst. Biol. 2009, 5:333.
25. Schumacher S., Laaß K., Kant S., Shi Y., Visel A., Gruber A.D., Kotlyarov A., Gaestel M. Scaffolding by ERK3 regulates MK5 in development. EMBO J. 2004, 23:4770-4779.
26. Seternes O.-M., Mikalsen T., Johansen B., Michaelsen E., Armstrong C.G., Morrice N.A., Turgeon B., Meloche S., Moens U., Keyse S.M. Activation of MK5 by the atypical MAP kinase ERK3 defines a novel signal transduction pathway. EMBO J. 2004, 23:4780-4791.
27. Aberg E., Perander M., Johansen B., Julien C., Meloche S., Keyse S.M., Seternes O.M. Regulation of MAPK-activated protein kinase 5 activity and subcellular localization by the atypical MAPK ERK4/MAPK4. J. Biol. Chem. 2006, 281:35499-35510.
28. Gaestel M. MAPKAP kinases - MKs - two's company, three's a crowd. Nat. Rev. Mol. Cell. Bio. 2006, 7:120-130.
29. Tak H., Jang E., Kim S.B., Park J., Suk J., Yoon Y.S., Ahn J.K., Lee J.H., Joe C.O. 14-3-3epsilon inhibits MK5-mediated cell migration by disrupting F-actin polymerization. Cell Signal. 2007, 19:2379-2387.
30. Deleris P., Rousseau J., Coulombe P., Rodier G., Tanguay P.L., Meloche S. Activation loop phosphorylation of the atypical MAP kinases ERK3 and ERK4 is required for binding, activation and cytoplasmic relocalization of MK5. J. Cell. Physiol. 2008, 217:778-788.